Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma

Table 3 Univariate and multivariate analyses of immunohistochemical expression, mucinous immunophenotypes, and chemotherapy for prolonging PFS in patients with mDJA

		Univariate analysis			Multivariate analysis
Variables	N	HR	95% CI	P value	HR	95% CI	P value
VEGF-A (high)	39	0.54	0.32–0.93	0.027	0.58	0.34–0.99	0.049
CD10 (positive)	48	0.77	0.43–1.39	0.396
MUC2 (positive)	50	0.57	0.31–1.06	0.078
MUC5AC (positive)	43	1.35	0.76–2.38	0.293
MUC6 (positive)	29	1.50	0.88–2.57	0.134
I-type	16	0.50	0.26–0.97	0.040	0.69	0.34–1.40	0.308
GI-type	43	1.33	0.75–2.35	0.316
G-type	5	2.38	0.93–6.05	0.068
TP53 (high)	27	0.75	0.44–1.29	0.307
Ki67 (high)	50	0.50	0.27–0.92	0.026	0.66	0.34–1.25	0.208
β-catenin (positive)	8	0.87	0.37–2.05	0.759
MMRD	3	1.38	0.33–3.00	0.652
Bevacizumab-containing chemotherapy ^a	10	0.43	0.18–1.01	0.054	0.61	0.25–1.49	0.285
Platinum-based chemotherapy ^b	47	0.59	0.33–1.05	0.074	0.69	0.37–1.27	0.241

PFS progression-free survival, mDJA metastatic duodenal and jejunal adenocarcinoma, CI confidence interval, HR hazard ratio, VEGF-A vascular endothelial growth factor A, I-type intestinal type, GI-type gastrointestinal type, G-type gastric type, MMRD mismatch repair protein deficiency, ^a The reference is “Chemotherapy without bevacizumab”, ^b The reference is “Monotherapy”

ISSN: 1471-2407